Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.
Ashley H McKnightMary L TownsendMohamed G HashemSusanna NaggieLawrence P ParkRachel B BrittPublished in: The Annals of pharmacotherapy (2020)
Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders.